Published in Cent European J Urol on April 19, 2016
The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab (2007) 8.91
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension (2007) 6.99
Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta (2006) 2.97
The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev (2012) 2.71
Vitamin D for cancer prevention: global perspective. Ann Epidemiol (2009) 2.61
Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer (2011) 2.43
The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer (2014) 2.41
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res (1990) 2.00
Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol (2011) 1.97
Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology (2000) 1.90
Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst (2012) 1.79
Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem (2013) 1.71
Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. Am J Clin Nutr (2013) 1.62
Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer. J Natl Cancer Inst (2013) 1.60
Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts. Br J Nutr (2012) 1.59
Gadd45a suppresses Ras-driven mammary tumorigenesis by activation of c-Jun NH2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res (2006) 1.49
Serum vitamin D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial. Cancer Epidemiol Biomarkers Prev (2012) 1.48
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer (2004) 1.45
Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control (2011) 1.43
Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol (2001) 1.40
Circulating 25-hydroxyvitamin D and risk of kidney cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol (2010) 1.40
The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am (2010) 1.37
Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev (2007) 1.30
Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab (2003) 1.30
Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol (2000) 1.26
Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol (2009) 1.24
Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res (2012) 1.24
1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis (2006) 1.20
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology (2009) 1.19
1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology (1997) 1.19
Serum vitamin D and risk of bladder cancer. Cancer Res (2010) 1.17
Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer (2008) 1.16
1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ (2000) 1.14
Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer (2006) 1.13
Circulating 25-hydroxyvitamin D3 in relation to renal cell carcinoma incidence and survival in the EPIC cohort. Am J Epidemiol (2014) 1.09
Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2009) 1.07
Vitamin D 25-hydroxylase - Four decades of searching, are we there yet? Arch Biochem Biophys (2012) 1.07
Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2014) 1.07
Does sunlight prevent cancer? A systematic review. Eur J Cancer (2006) 1.07
Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer (2012) 1.06
Micronutrients and the risk of renal cell cancer: a case-control study from Italy. Int J Cancer (2007) 1.05
Minerals and vitamins and the risk of bladder cancer: results from the New Hampshire Study. Cancer Causes Control (2009) 1.05
Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology (1997) 1.04
Association of vitamin-D receptor (Fok-I) gene polymorphism with bladder cancer in an Indian population. BJU Int (2007) 1.03
Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer (2012) 1.02
Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev (2009) 1.02
25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol (2002) 1.01
Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer (2011) 1.01
Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control (2012) 1.01
Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res (2013) 1.00
Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2014) 1.00
Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet (2009) 0.99
Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol (2001) 0.98
Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr (2012) 0.98
25-hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem (2005) 0.97
Vitamin D in combination cancer treatment. J Cancer (2010) 0.96
5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res (1999) 0.96
Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. J Steroid Biochem Mol Biol (2010) 0.96
Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol (2014) 0.95
Are low ultraviolet B and high animal protein intake associated with risk of renal cancer? Int J Cancer (2006) 0.93
1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer (2010) 0.92
Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer (2011) 0.92
Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study. J Natl Cancer Inst (2012) 0.91
Current progress in using vitamin D and its analogs for cancer prevention and treatment. Expert Rev Anticancer Ther (2012) 0.91
Fish, vitamin D, and flavonoids in relation to renal cell cancer among smokers. Am J Epidemiol (2009) 0.91
Vitamin d pathway genes, diet, and risk of renal cell carcinoma. Int J Endocrinol (2009) 0.91
1,25 Dihydroxyvitamin D(3) receptor expression in superficial transitional cell carcinoma of the bladder: a possible prognostic factor? Eur Urol (2005) 0.90
Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology (2010) 0.90
VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res (2008) 0.90
Vitamin D-binding protein, circulating vitamin D and risk of renal cell carcinoma. Int J Cancer (2014) 0.89
Prostate Cancer Screening and the Associated Controversy. Surg Clin North Am (2015) 0.89
A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother Pharmacol (2009) 0.89
Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies. FASEB J (2013) 0.88
Vitamin d, sunlight and prostate cancer risk. Adv Prev Med (2011) 0.87
Inhibitory effect of 1 alpha,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line. Kidney Int (1986) 0.87
Prevention of renal cell carcinoma by active vitamin D3. World J Surg (2000) 0.87
Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-analysis involving 21,756 subjects. Tumour Biol (2013) 0.87
Vitamin D metabolism and action in the prostate: implications for health and disease. Mol Cell Endocrinol (2011) 0.86
Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol (1998) 0.84
Impact of serum vitamin D level on risk of bladder cancer: a systemic review and meta-analysis. Tumour Biol (2014) 0.84
1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer. Oncotarget (2013) 0.84
Expression and function of the vitamin D receptor in malignant germ cell tumour of the testis. Anticancer Res (2012) 0.84
Vitamin D metabolism and effects on pluripotency genes and cell differentiation in testicular germ cell tumors in vitro and in vivo. Neoplasia (2012) 0.83
Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population. Gene (2013) 0.83
Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies. Invest New Drugs (2012) 0.83
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res (Phila) (2010) 0.83
Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma. Carcinogenesis (2012) 0.82
Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model. J Steroid Biochem Mol Biol (2012) 0.82
Vitamin D: a modulator of cell proliferation and differentiation. J Steroid Biochem Mol Biol (1990) 0.81
Vitamin D receptor gene polymorphisms in breast and renal cancer: current state and future approaches (review). Int J Oncol (2013) 0.80
Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2014) 0.79
Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. Cancer Causes Control (2014) 0.79
Testicular maturation arrest to testis cancer: spectrum of expression of the vitamin D receptor and vitamin D treatment in vitro. J Urol (2007) 0.78
The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature. Neuro Endocrinol Lett (2013) 0.77
The association between VDR polymorphisms and renal cell carcinoma susceptibility: a meta-analysis. Tumour Biol (2014) 0.77
Association of vitamin D receptor gene polymorphism with the risk of renal cell carcinoma: a meta-analysis. J Recept Signal Transduct Res (2014) 0.76
Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients. Clin Cancer Res (2014) 0.76